Search Articles
Filter Articles
Open filtersClose filters
Sections
- All (3,657 articles)
- Pharma Events (45 articles)
- For Recruiters (265 articles)
- Careers Events (7 articles)
- Partners (3 articles)
- News (3,050 articles)
- Careers Advice (289 articles)
- Company Focus (193 articles)
- Company Career Hubs (1 article)
- Pharma Training (7 articles)
- 25 Years of PharmiWeb (13 articles)
- DE&I (2 articles)
Found 3,657 articles
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
- 25 Oct 2024
Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (CSU) who receive background therapy with antihistamines will be presented.
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
- 25 Oct 2024
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid, Spain.
About Akiram Therapeutics
- 24 Oct 2024
Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component.
Bayer partners with innovative hormone monitoring device start-up
- 24 Oct 2024
Bayer today announced a partnership with Impli, an innovative, deep-tech start-up in precision care. Impli’s goal is to advance women’s health and deliver the first real-time hormone monitoring device – making fertility more accessible, safer and more successful.
CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older
- 24 Oct 2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines and recommends CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for pneumococcal vaccination in adults 50 years of age and older.
-
Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
- 24 Oct 2024
Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in eligible adults in Great Britain.
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
- 24 Oct 2024
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal vaccines, including PREVNAR 20 ® (20-valent Pneumococcal Conjugate Vaccine) for all adults aged 50 and older.
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
- 24 Oct 2024
GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised.
How AI is Impacting Graduate Recruitment
- 23 Oct 2024
Applications to graduate schemes are up 59% compared to 2023, according to the Institute of Student Employers (ISE). Despite applications being on the rise, demand for graduates is down, as seen in the decrease in graduate vacancies in all sectors – including Healthcare & Nursing and Scientific & QA – except for Teaching and Customer Services.
About Wobble Genomics
- 23 Oct 2024
Wobble Genomics is an innovative healthcare and biotechnology company at the forefront of long-read RNA sequencing whose mission is to understand cancer in a new way. The company was founded by Dr Richard Kuo during his PHD at the home of genomics, The Roslin Institute, at The University of Edinburgh.
Ten businesses embark on Discovery Park’s ‘Discovery Spark’ programme
- 23 Oct 2024
In a bid to enable future success and growth, ten entrepreneurial life science and technology businesses have begun the immersive Discovery Spark programme, with a prize package worth over £50,000 up for grabs.
Parexel Names Keri Mattox Chief Business Officer
- 23 Oct 2024
Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Keri Mattox to the newly created role of Chief Business Officer.
FDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy for Patients with Grade 2 IDH-Mutant Glioma
- 23 Oct 2024
Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals, LLC’s VORANIGO® (vorasidenib) tablets.
Evotec and Bristol Myers Squibb expand proteomics partnership
- 23 Oct 2024
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease
- 22 Oct 2024
GSK plc (LSE/NYSE: GSK) announced it is investing £50 million into a major new five-year collaboration with the University of Cambridge and Cambridge University Hospitals, to accelerate research and development into immune-related diseases.
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System
- 21 Oct 2024
Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW™ Software.
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
- 21 Oct 2024
Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
- 21 Oct 2024
Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.
Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
- 21 Oct 2024
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo® (faricimab) for the treatment of diabetic macular edema (DME) in people from racial and ethnic groups that are often underrepresented in clinical trials.
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
- 21 Oct 2024
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir.